The Use of PCSK9 Inhibitors During the Acute Phase of ACS: Latest Clinical Evidence and a Look Into the Future

11 Jul 2022
The Use of PCSK9 Inhibitors During the Acute Phase of ACS:
Latest Clinical Evidence and a Look Into the Future
At a recent symposium, experts in cardiology discussed the latest clinical trial data and their experience using proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9is) in the management of patients with acute coronary syndrome (ACS)

Related MIMS Drugs

Editor's Recommendations